Clinical Edge Journal Scan

Early BC patients with small tumors and negative axillary lymph node ultrasound may skip axillary surgery


 

Key clinical point: The omission of axillary surgery leads to non-inferior outcomes compared to sentinel lymph node biopsy (SLNB) and may not be necessary in patients with early breast cancer (BC) having a tumor diameter ≤ 2 cm and negative results for preoperative axillary lymph node ultrasonography.

Major finding: The rates of 5-year distant disease-free survival were comparable in patients who underwent SLNB and those who did not undergo axillary surgery (97.7% vs 98.0%; hazard ratio 0.84; noninferiority P = .02).

Study details: Findings are from the phase 3 SOUND trial including 1405 women with BC having a tumor diameter ≤ 2 cm and negative preoperative axillary ultrasonography results who were randomly assigned to undergo either SLNB or no axillary surgery.

Disclosures: This study did not disclose any funding source. Some authors declared receiving personal fees from various sources.

Source: Gentilini OD et al for the SOUND Trial Group. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: The SOUND randomized clinical trial. JAMA Oncol. 2023 (Sep 21). doi: 10.1001/jamaoncol.2023.3759

Recommended Reading

Commentary: Radiation therapy, endocrine therapy, metformin, and statins in breast cancer, October 2023
MDedge Hematology and Oncology
USPSTF should reconsider recommendation to lower mammogram age: Experts
MDedge Hematology and Oncology
SABR could defer systemic therapy in oligoprogressive breast cancer
MDedge Hematology and Oncology
Adopting high-dose radiation vs. conventional after mastectomy could be ‘game changer’
MDedge Hematology and Oncology
‘Reassuring’ follow-up validates radiation strategy for early breast cancer
MDedge Hematology and Oncology
Does surgery improve survival in metastatic breast cancer?
MDedge Hematology and Oncology
This is how you get patients back for follow-up cancer testing
MDedge Hematology and Oncology
Breast reconstruction post mastectomy: What matters most to women?
MDedge Hematology and Oncology
What the first authorized DNA cancer risk test can and can’t tell you
MDedge Hematology and Oncology
Male patients with breast cancer: Special considerations and gender-specific concerns
MDedge Hematology and Oncology